How Novartis’s Business Segments Did in Q1
As discussed earlier, Novartis’s (NVS) revenue grew 10% YoY (year-over-year) in the first quarter, to ~$12.7 billion from ~$11.5 billion. Novartis breaks down its business into three segments: Innovative Medicines, which includes prescription medicines Sandoz, its generics business Alcon, its eyecare business